Compare Ares Capital Corporation (ARCC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs Viatris Inc — how do they compare? Ares Capital Corporation trades at $19.96 (market cap $14.34B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is the larger of the two by market cap, and Ares Capital Corporation pays the higher dividend (9.61%). Which is the better fit depends on your goals.
| ARCC | VTRS | |
|---|---|---|
Market Cap | $14.34B | $18.69B |
Sector | Financials | Health |
52-Week High | $22.68 | $17.86 |
52-Week Low | $17.45 | $9.49 |
Dividend Yield | 9.61% | 2.95% |
Enterprise Value | — | $30.80B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
